Literature DB >> 16408110

Kidney cancer: identification of novel targets for therapy.

R H Weiss1, P-Y Lin.   

Abstract

Kidney cancer, although relatively rare when compared to other malignancies, occurs not uncommonly in patients with renal disease and is often discovered incidentally during the initial nephrologic work-up, or by the savvy clinician who is familiar with the paraneoplastic signs. While surgical approaches are generally curative when the disease is confined to the kidney, one-third of the cases that present in the metastatic form and require conventional medical therapy are associated with a truly dismal patient survival rate. In light of the emerging knowledge of the molecular mechanisms of kidney cancer oncogenesis, several novel and promising therapeutic approaches are emerging. In this review, we summarize the current state of kidney cancer diagnosis and therapy, as well as some of the novel treatments that capitalize on those newly elucidated molecular pathways that are deranged in this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16408110     DOI: 10.1038/sj.ki.5000065

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  49 in total

1.  2-Hydroxyestradiol slows progression of experimental polycystic kidney disease.

Authors:  Sharon Anderson; Terry T Oyama; Jessie N Lindsley; William E Schutzer; Douglas R Beard; Vincent H Gattone; Radko Komers
Journal:  Am J Physiol Renal Physiol       Date:  2011-12-07

2.  Down-regulation of 20-HETE synthesis and signaling inhibits renal adenocarcinoma cell proliferation and tumor growth.

Authors:  Anna Alexanian; Victoriya A Rufanova; Bradley Miller; Averia Flasch; Richard J Roman; Andrey Sorokin
Journal:  Anticancer Res       Date:  2009-10       Impact factor: 2.480

3.  Urinary acylcarnitines are altered in human kidney cancer.

Authors:  Sheila Ganti; Sandra L Taylor; Kyoungmi Kim; Charles L Hoppel; Lining Guo; Joy Yang; Christopher Evans; Robert H Weiss
Journal:  Int J Cancer       Date:  2011-09-14       Impact factor: 7.396

4.  Addition of DHA Synergistically Enhances the Efficacy of Regorafenib for Kidney Cancer Therapy.

Authors:  Jeffrey Kim; Arzu Ulu; Debin Wan; Jun Yang; Bruce D Hammock; Robert H Weiss
Journal:  Mol Cancer Ther       Date:  2016-02-26       Impact factor: 6.261

5.  Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer.

Authors:  Kyoungmi Kim; Sandra L Taylor; Sheila Ganti; Lining Guo; Michael V Osier; Robert H Weiss
Journal:  OMICS       Date:  2011-02-24

Review 6.  Metabolic reprogramming in clear cell renal cell carcinoma.

Authors:  Hiromi I Wettersten; Omran Abu Aboud; Primo N Lara; Robert H Weiss
Journal:  Nat Rev Nephrol       Date:  2017-05-08       Impact factor: 28.314

Review 7.  Potential biofluid markers and treatment targets for renal cell carcinoma.

Authors:  Hiromi I Wettersten; Robert H Weiss
Journal:  Nat Rev Urol       Date:  2013-04-02       Impact factor: 14.432

Review 8.  Prognostic role of microvessel density in patients with renal cell carcinoma: a meta-analysis.

Authors:  Si-Hang Cheng; Jia-Ming Liu; Qin-Yu Liu; De-Yi Luo; Bang-Hua Liao; Hong Li; Kun-Jie Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

9.  CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth.

Authors:  Hiromi Inoue; Michael Kauffman; Sharon Shacham; Yosef Landesman; Joy Yang; Christopher P Evans; Robert H Weiss
Journal:  J Urol       Date:  2012-10-16       Impact factor: 7.450

10.  Expression of hypoxia-inducible protein 2 in renal cell carcinoma: A promising candidate for molecular targeting therapy.

Authors:  Takashi Seo; Ryuichiro Konda; Jun Sugimura; Kazuhiro Iwasaki; Yusuke Nakamura; Tomoaki Fujioka
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.